Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
Notes underwriting agrmnt
Histogen Inc. (CNAT) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement  Interactive Data
09/26/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
08/15/2023 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
07/05/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Histogen to Explore Strategic Alternatives SAN DIEGO, July 5, 2023 – Histogen Inc. , a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function, today announced that it has completed a review of its business, including the status of programs, resources and capabilities, and has decided to pause further development of its programs and commence a process to explore strategic alternatives with the intent to enhance shareholder value. Histogen has engaged Roth Capital Partners, LLC, to act as a strategic advisor in this process. Potential strategic alternatives that may be explored or evaluated as part of this process ..."
05/11/2023 8-K Quarterly results
Docs: "Histogen Reports First Quarter 2023 Results and Provides Business Update Received FDA Clearance of IND Application for Emricasan for the Treatment of Acute Bacterial Skin and Skin Structure Infections Emricasan Treatment has Therapeutic Effect Against Bacterial Skin Infection in Mice Signed Exclusive Intellectual Property License Agreement with Johns Hopkins University Steven J. Mento Ph.D. Appointed President and CEO SAN DIEGO, May 11, 2023 – Histogen Inc. , a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function, today reported financial results for the first quarter ended March 31, 2023, and provided an updat..."
04/03/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Histogen Announces Exclusive Intellectual Property License Agreement with Johns Hopkins University Licensed Patents Expected to Provide Freedom to Operate and Exclusivity for Emricasan Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases SAN DIEGO, April 3, 2023 – Histogen Inc. , a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function, today announced that the company has signed an exclusive license agreement with Johns Hopkins University. The intellectual property associated with this license covers the use of emricasan for the treatment of disease in humans re..."
03/09/2023 8-K Quarterly results
Docs: "Histogen Reports Year-End 2022 Results and Provides Business Update Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases SAN DIEGO, March 9, 2023 – Histogen Inc. , a clinical-stage therapeutics company on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function, today reported financial results for the year ended December 31, 2022, and provided an update on its pipeline and other corporate developments. “Our team is very excited about the new direction of the company. We remain focused on the development of emricasan as a potential treatment for acute bacterial skin and skin structure infections , includ..."
01/03/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT is entered into as of February 1, 2023 , by and between Histogen Inc., a Delaware corporation , and Alfred P. Spada Ph.D. . RECITALS WHEREAS, Employer wishes to engage Executive as Executive Vice President and Chief Scientific Officer on the terms and conditions hereinafter set forth. AGREEMENT NOW THEREFORE, in consideration of the foregoing premises and the mutual covenants and agreements set forth herein, Executive and Employer agree as follows: 1. Employment Term. The term of this Agreement shall commence on the Effective Date and will continue until terminated as provided in Section 7 below. 2. Scope of Employment. a. Position and Duties. Executive shall serve as Company’s CSO. Executive agrees that during the Employme...",
"Histogen Hires Alfred P. Spada Ph.D. as Executive Vice President and Chief Scientific Officer Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases SAN DIEGO, January 3, 2023 -- Histogen Inc. , a clinical-stage therapeutics company focused on developing its pan-caspase and caspase selective inhibitors as treatments for infectious and inflammatory diseases and has a pipeline of restorative therapeutics for orthopedic indications, today announced the appointment of Alfred P. Spada Ph.D. as Executive Vice President and Chief Scientific Officer. “We are very excited about Dr. Spada joining our management team. Dr. Spada is a world expert in both the biology of apoptosis and the chemistry of designing potent caspase inhibitors,” sa..."
12/02/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
Docs: "Histogen Reports Third Quarter 2022 Financial Results and Provides Business Update SAN DIEGO, Nov. 10, 2022 – Histogen Inc. , a clinical-stage therapeutics company focused on developing both restorative therapeutics for orthopedic indications and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today reported financial results for the third quarter ended September 30, 2022 and provided an update on its clinical pipeline and other corporate developments. “We remain focused on the feasibility of developing emricasan as a potential treatment for bacterial skin infections including those related to methicillin resistant staphylococcus aureus and evaluating our caspase-1 inhibitors that impact the inflammasome pathway,” s..."
08/11/2022 8-K Quarterly results
07/12/2022 8-K Quarterly results
06/30/2022 8-K Quarterly results
06/17/2022 8-K Quarterly results
06/07/2022 8-K Quarterly results
06/02/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
04/29/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Consulting Agreement, by and between the Company and Latterich Consulting Service LLC"
03/25/2022 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Amendments to Articles of I...
Docs: "Bylaw Amendment",
"Bylaw Amendment",
"Certificate of Designation of Preferences, Rights and Limitations of Series A Redeemable Convertible Preferred Stock",
"Certificate of Designation of Preferences, Rights and Limitations of Series B Redeemable Convertible Preferred Stock",
"Form of Placement Agent Warrant",
"Form of Securities Purchase Agreement between Histogen Inc. and the investors therein",
"Form of Registration Rights Agreement between Histogen Inc. and the investors therein",
"Engagement Letter, between the Company and H.C. Wainwright & Co., LLC",
"Histogen Announces $4.75 Million Private Placement",
"Histogen Announces Closing of $4.75 Million Private Placement"
03/22/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Letter Agreement by and between Histogen, Inc. and Allergan Sales, LLC"
03/10/2022 8-K Quarterly results
Docs: "Histogen Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update Phase 1/2 Study of HST 003 for Cartilage Regeneration in the Knee Ongoing with Top-Line Data Anticipated in the First Half of 2023"
02/22/2022 8-K Quarterly results
02/15/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
12/16/2021 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Form of Warrant",
"Form of Placement Agent Warrant",
"Form of Securities Purchase Agreement",
"Form of Registration Rights Agreement",
"Histogen Announces $3.5 Million Private Placement"
11/10/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/10/2021 8-K Quarterly results
Docs: "Histogen Reports Third Quarter 2021 Earnings and Provides Business Update Phase 1/2 Study of HST 003 for Cartilage Regeneration in the Knee On- Going with Top-Line Data Expected in the Second Half of 2022"
11/08/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Executive Agreement, by and between the Company and Steven J. Mento, Ph.D",
"Histogen Announces CEO Transition November 8, 2021 San Diego Calif., Nov. 8, 2021 — Histogen Inc. , a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function, today announced that that Steven J. Mento, Ph.D., a current member of the Histogen Board of Directors, has been appointed Executive Chairman and Interim President and Chief Executive Officer effective immediately. David Crean, Ph.D., a current member and the Chairman of the Histogen Board of Directors, will continue to serve as a member of the Board of Directors and as the newly appointed Lead Independent Director. Richard Pascoe has stepped down as President and Chief Executive Officer and as ..."
08/20/2021 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
08/11/2021 8-K Quarterly results
06/25/2021 8-K Quarterly results
06/09/2021 8-K Quarterly results
06/08/2021 8-K Quarterly results
06/03/2021 8-K Quarterly results
05/27/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy